Previous 10 | Next 10 |
Checkpoint Therapeutics (NASDAQ: CKPT ): FY GAAP EPS of -$0.70 misses by $0.05 . More news on: Checkpoint Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor...
Intro Checkpoint Therapeutics ( CKPT ) is a majority-controlled subsidiary of Fortress Biotech ( FBIO ). The Company is focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumors. Its lead candidates are CK-101, which is in Phase 1/2 cli...
FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trial One-third enrollment complete in cohort of patients with metastatic cutaneous squamous cell carcinoma Potential for cosibelimab to be differentiated and lower-cost alter...
The Netflix Prize The Netflix Prize was a competition begun in 2006 to predict user ratings for films. Competitors were given ratings scrubbed of information about the users and were challenged to find, using machine-learning methods, an algorithm based only on the raw data. Netflix provid...
Checkpoint Therapeutics ( CKPT -16% ) prices its underwritten public offering of 13.4M shares at $1.27 per share; the offering is expected close by Nov. 22. More news on: Checkpoint Therapeutics, Inc., Healthcare stocks news Read more ...
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously announced underwritten public offering. Checkpoint is offering 1...
NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common sto...
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic and target occupancy modeling data for cosibelimab (formerly referred to as CK-301) a...
Checkpoint Therapeutics (NASDAQ: CKPT ): Q3 GAAP EPS of -$0.15 beats by $0.02 . More news on: Checkpoint Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...